CACNA1A and episodic ataxia type 2: With the number of the mutations identified in 15 of 31 (48.4%) of the EA2 patients tested our newly developed custom panel provides an improved diagnostics tool compared to traditional exon‐by‐exon sequencing widely used in laboratories to identify the genetic aberrations of patients sharing overlapping symptoms with EA2, such as FHM and SCA6.